School of Medicine
Showing 1-10 of 61 Results
-
Jennifer Carlson
Clinical Professor, Pediatrics - Adolescent Medicine
Current Research and Scholarly InterestsMy research interests and scholarship fall into two major "buckets" of activity: 1) confidentiality and clinical informatics and 2) eating disorders, particularly the Female/Male Athlete Triad.
-
Suzan Carmichael
Professor (Research) of Pediatrics (Neonatology), of Obstetrics & Gynecology (Maternal Fetal Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Carmichael is a perinatal and nutritional epidemiologist and Professor of Pediatrics and Obstetrics and Gynecology at the Stanford University School of Medicine.
Her team is committed to finding ways to improve maternal and infant health outcomes and equity by leading research that identifies effective leverage points for change, from upstream 'macro' social and structural factors, to downstream clinical factors (eg, related to care and morbidities) through a collaborative research approach that integrates epidemiologic approaches with community engagement and systems thinking.
Exposure themes include social context, nutrition, care, environmental contaminants and genetics. Outcome themes include severe maternal morbidity, stillbirth, birth defects, and preterm delivery. She is particularly interested in understanding the intersectionality of these varied types of exposures and outcomes and how they interact to impact health and health disparities, for the mother-baby dyad.
Please see the team web-site for further information!
https://med.stanford.edu/carmichaellab.html -
Ricardo Castillo
Associate Professor of Pediatrics (Gastroenterology) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsStudy of the interaction and role of nutrients and intestinal growth factors in enhancing intestinal adaptation and allograft viability using animal models for short bowel syndrome and orthtopic intestinal transplantation.
Study of immunosuppression regimens and induction of immune tolerance in intestinal transplantation. -
Robert Castro
Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
Current Research and Scholarly InterestsNeonatal Fluid Balance
Surfactant
Lung Fluid Reabsorption -
Alma-Martina Cepika
Instructor, Pediatrics - Stem Cell Transplantation
BioDr. Cepika is an immunologist with an extensive background in translational research, autoimmunity, autoinflammation, and human systems immunology. Her goal is to understand the mechanisms governing immunological tolerance, and to leverage this knowledge to cure currently incurable diseases.
Dr. Cepika received her MD degree and a PhD in Immunology from the University of Zagreb School of Medicine in Croatia. There, she focused on the immunomonitoring of patients with lupus, identifying how circulating DNA levels changed with therapy. Subsequently, she joined the lab of Dr. Virginia Pascual at the Baylor Institute for Immunology Research in Dallas, Texas. Dr. Pascual had previously discovered that IL-1beta is a key pathogenic player in systemic juvenile idiopathic arthritis (sJIA), but the immune alterations contributing to IL-1beta-mediated inflammation remained unknown. To address this, Dr. Cepika developed a 3D in vitro stimulation assay to evaluate immune responses of blood leukocytes of pediatric sJIA patients. In combination with integrated bioinformatics analysis, this approach identified aberrant cellular responses, transcriptional pathways and genes that shed new light on immune dysregulation in sJIA. This assay can be further applied to dissect underlying immunopathogenic mechanisms in many human disorders.
Currently, Dr. Cepika is a member of the laboratory of Dr. Maria Grazia Roncarolo, in the Pediatric Division of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine. There, she is working to uncover the underlying mechanisms governing type 1 regulatory T (Tr1) cell differentiation and function, and use this knowledge to design Tr1 cell-based therapies for hematopoietic stem cell transplantation, cancer immunotherapy and autoimmunity.
